An experimental drug being trialled for advanced tumours has passed phase one of its Australian trial, with the second phase set to test the drug’s effectiveness against the most aggressive brain cancer—glioblastoma.
Starting in June 2021, the first phase involved patients with glioblastoma, as well as cervical, pancreatic, colon, gastrointestinal, and uterine cancers, with the aim of testing whether the drug Auceliciclib was safe at different dosages.
